Novavax Inc. Stock Rises Wednesday, Still Underperforms Market

Silk Road Medical Inc

Change company Symbol lookup

Select an option...

SILK Silk Road Medical Inc

HLVX Hillevax Inc

AIZ Assurant Inc

NOTV Inotiv Inc

MYD BlackRock MuniYield

WPC WP Carey Inc

ATCO-I Atlas Corp

ATLX Atlas Lithium Corp

SRRK Scholar Rock Holding Corp

SCLX Scilex Holding Co

Health Care : Health Care Equipment & Supplies | Small Cap Blend

Company profile

Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.

Novavax Inc. Stock Rises Wednesday, Still Underperforms Market

5:14 pm ET November 23, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) inched 0.65% higher to $17.03 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 0.99% to 11,285.32 and the Dow Jones Industrial Average rising 0.28% to 34,194.06. The stock's rise snapped a five-day losing streak. Novavax Inc. closed $219.47 short of its 52-week high ($236.50), which the company reached on December 20th.

The stock outperformed some of its competitors Wednesday, as Replimune Group Inc. (REPL) fell 1.36% to $19.57, VBI Vaccines Inc. (VBIV) fell 0.54% to $0.59, and AnaptysBio Inc. (ANAB) rose 0.04% to $27.95. Trading volume (3.7 M) remained 1.5 million below its 50-day average volume of 5.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 23, 2022.

(END) Dow Jones Newswires

November 23, 2022 17:14 ET (22:14 GMT)